Report Detail
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Report, History and Forecast 2017-2028, Breakdown Data by Companies, Key Regions, Types and Application
- RnM4387727 |
- 23 February, 2022 |
- Global |
- 113 Pages |
- QYResearch |
- Medical Industry
Summary:
Market Insights
The research report studies the SERD (Selective Estrogen Receptor Degrader) Drugs market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
Due to the COVID-19 pandemic, the global SERD (Selective Estrogen Receptor Degrader) Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028.
The global main companies of SERD (Selective Estrogen Receptor Degrader) Drugs include Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy's Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG and InventisBio, etc. In 2021, the global six largest players have a share approximately % in terms of revenue.
The North America SERD (Selective Estrogen Receptor Degrader) Drugs market is estimated at US$ million in 2021, while China is forecast to reach US$ million by 2028. The proportion of the China is % in 2021 and it is predicted that the share will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. As for the Europe SERD (Selective Estrogen Receptor Degrader) Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
RAD1901 accounting for % of the SERD (Selective Estrogen Receptor Degrader) Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While First-Line Treatment segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
Segment Scope
An intensive study of key type and application segments has been done in this segmentation section. The authors of the report have provided reliable figures including revenue forecast data by type and application for the period 2017-2028. They have also studied how the segments are gaining or losing growth in various geographies and their respective countries. Thanks to this study, readers can thoroughly grasp the growth pattern and potential of different segments.
Segment by Type
RAD1901
GDC-9545
AZD9833
SAR439859
Faslodex
Others
Segment by Application
First-Line Treatment
Second-Line Treatment
Regional Scope
This segment of the report offers a thorough regional study of the global SERD (Selective Estrogen Receptor Degrader) Drugs market. Drivers and restraints for each region are broadly examined in the report. Readers will get familiar with the driving forces and challenges that are specific to the regions. The specialists have identified growth opportunities in key geographical regions and their respective countries to aid players to reinforce their presence. All the regions and their countries in the report are assessed based on the growth rate and revenue according to the consumption for the period 2017-2028. This geographical analysis will help readers to gain in-depth knowledge of the regional growth. The key geographical regions surveyed in this research report involve North America, Europe, Asia Pacific, Central and South America, and Middle East and Africa. The report has specifically covered major countries including United States, Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
Key Players
This section has provided an exhaustive analysis of the strategies that the companies are focusing on to stay ahead of other players. The strategies mainly involve research and development, new product developments, and mergers and acquisitions. The researchers have also provided revenue shares of the key companies, company overview, and the latest company developments so as to help players to sustain the cutthroat competition. In this section, the report offers global revenue data of manufacturers for the period 2017-2022. Following is the list of key manufacturers observed in this research study:
Amneal Pharmaceuticals Inc
AstraZeneca, Plc.
Dr. Reddy's Laboratories
Eli Lilly and Company
G1 Therapeutics, Inc.
Glenmark Pharmaceuticals
HBT Labs, Inc
Hoffmann-La Roche AG
InventisBio
Novartis AG
Radius Health
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zenopharm LLC.
Zentalis Pharmaceuticals
Frequently Asked Questions
Which application segment captured the leading share in the SERD (Selective Estrogen Receptor Degrader) Drugs market?
How fragmented is the SERD (Selective Estrogen Receptor Degrader) Drugs market?
Which are the key growth drivers in the SERD (Selective Estrogen Receptor Degrader) Drugs market?
Which are the top strategies undertaken by the SERD (Selective Estrogen Receptor Degrader) Drugs market players?
Which technological trends are likely to affect the SERD (Selective Estrogen Receptor Degrader) Drugs market?
What is the expected SERD (Selective Estrogen Receptor Degrader) Drugs market size by 2028?
Which companies are dominating the SERD (Selective Estrogen Receptor Degrader) Drugs market?
Which region is projected to witness the fastest growth in the future?
What factors are restraining the SERD (Selective Estrogen Receptor Degrader) Drugs market growth?
Which are the emerging companies in the SERD (Selective Estrogen Receptor Degrader) Drugs market?
Table of Contents
1 Market Overview of SERD (Selective Estrogen Receptor Degrader) Drugs
- 1.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Overview
- 1.1.1 SERD (Selective Estrogen Receptor Degrader) Drugs Product Scope
- 1.1.2 SERD (Selective Estrogen Receptor Degrader) Drugs Market Status and Outlook
- 1.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Overview by Region 2017 VS 2021 VS 2028
- 1.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2017-2028)
- 1.4 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Region (2017-2022)
- 1.5 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Forecast by Region (2023-2028)
- 1.6 Key Regions, SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
- 1.6.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
- 1.6.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
- 1.6.3 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
- 1.6.4 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
- 1.6.5 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
2 SERD (Selective Estrogen Receptor Degrader) Drugs Market Overview by Type
- 2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type: 2017 VS 2021 VS 2028
- 2.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Type (2017-2022)
- 2.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Type (2023-2028)
- 2.4 RAD1901
- 2.5 GDC-9545
- 2.6 AZD9833
- 2.7 SAR439859
- 2.8 Faslodex
- 2.9 Others
3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Overview by Application
- 3.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application: 2017 VS 2021 VS 2028
- 3.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Application (2017-2022)
- 3.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Application (2023-2028)
- 3.4 First-Line Treatment
- 3.5 Second-Line Treatment
4 SERD (Selective Estrogen Receptor Degrader) Drugs Competition Analysis by Players
- 4.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Players (2017-2022)
- 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs as of 2021)
- 4.3 Date of Key Players Enter into SERD (Selective Estrogen Receptor Degrader) Drugs Market
- 4.4 Global Top Players SERD (Selective Estrogen Receptor Degrader) Drugs Headquarters and Area Served
- 4.5 Key Players SERD (Selective Estrogen Receptor Degrader) Drugs Product Solution and Service
- 4.6 Competitive Status
- 4.6.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Concentration Rate
- 4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
- 5.1 Amneal Pharmaceuticals Inc
- 5.1.1 Amneal Pharmaceuticals Inc Profile
- 5.1.2 Amneal Pharmaceuticals Inc Main Business
- 5.1.3 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.1.4 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.1.5 Amneal Pharmaceuticals Inc Recent Developments
- 5.2 AstraZeneca, Plc.
- 5.2.1 AstraZeneca, Plc. Profile
- 5.2.2 AstraZeneca, Plc. Main Business
- 5.2.3 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.2.4 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.2.5 AstraZeneca, Plc. Recent Developments
- 5.3 Dr. Reddy's Laboratories
- 5.3.1 Dr. Reddy's Laboratories Profile
- 5.3.2 Dr. Reddy's Laboratories Main Business
- 5.3.3 Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.3.4 Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.3.5 Eli Lilly and Company Recent Developments
- 5.4 Eli Lilly and Company
- 5.4.1 Eli Lilly and Company Profile
- 5.4.2 Eli Lilly and Company Main Business
- 5.4.3 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.4.4 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.4.5 Eli Lilly and Company Recent Developments
- 5.5 G1 Therapeutics, Inc.
- 5.5.1 G1 Therapeutics, Inc. Profile
- 5.5.2 G1 Therapeutics, Inc. Main Business
- 5.5.3 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.5.4 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.5.5 G1 Therapeutics, Inc. Recent Developments
- 5.6 Glenmark Pharmaceuticals
- 5.6.1 Glenmark Pharmaceuticals Profile
- 5.6.2 Glenmark Pharmaceuticals Main Business
- 5.6.3 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.6.4 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.6.5 Glenmark Pharmaceuticals Recent Developments
- 5.7 HBT Labs, Inc
- 5.7.1 HBT Labs, Inc Profile
- 5.7.2 HBT Labs, Inc Main Business
- 5.7.3 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.7.4 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.7.5 HBT Labs, Inc Recent Developments
- 5.8 Hoffmann-La Roche AG
- 5.8.1 Hoffmann-La Roche AG Profile
- 5.8.2 Hoffmann-La Roche AG Main Business
- 5.8.3 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.8.4 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.8.5 Hoffmann-La Roche AG Recent Developments
- 5.9 InventisBio
- 5.9.1 InventisBio Profile
- 5.9.2 InventisBio Main Business
- 5.9.3 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.9.4 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.9.5 InventisBio Recent Developments
- 5.10 Novartis AG
- 5.10.1 Novartis AG Profile
- 5.10.2 Novartis AG Main Business
- 5.10.3 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.10.4 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.10.5 Novartis AG Recent Developments
- 5.11 Radius Health
- 5.11.1 Radius Health Profile
- 5.11.2 Radius Health Main Business
- 5.11.3 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.11.4 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.11.5 Radius Health Recent Developments
- 5.12 Sanofi S.A.
- 5.12.1 Sanofi S.A. Profile
- 5.12.2 Sanofi S.A. Main Business
- 5.12.3 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.12.4 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.12.5 Sanofi S.A. Recent Developments
- 5.13 Teva Pharmaceutical Industries Ltd.
- 5.13.1 Teva Pharmaceutical Industries Ltd. Profile
- 5.13.2 Teva Pharmaceutical Industries Ltd. Main Business
- 5.13.3 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.13.4 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 5.14 Zenopharm LLC.
- 5.14.1 Zenopharm LLC. Profile
- 5.14.2 Zenopharm LLC. Main Business
- 5.14.3 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.14.4 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.14.5 Zenopharm LLC. Recent Developments
- 5.15 Zentalis Pharmaceuticals
- 5.15.1 Zentalis Pharmaceuticals Profile
- 5.15.2 Zentalis Pharmaceuticals Main Business
- 5.15.3 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Products, Services and Solutions
- 5.15.4 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$ Million) & (2017-2022)
- 5.15.5 Zentalis Pharmaceuticals Recent Developments
6 North America
- 6.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2028)
- 6.2 United States
- 6.3 Canada
7 Europe
- 7.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2028)
- 7.2 Germany
- 7.3 France
- 7.4 U.K.
- 7.5 Italy
- 7.6 Russia
8 Asia-Pacific
- 8.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2017-2028)
- 8.2 China
- 8.3 Japan
- 8.4 South Korea
- 8.5 India
- 8.6 Australia
- 8.7 China Taiwan
- 8.8 Indonesia
9 Latin America
- 9.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2028)
- 9.2 Mexico
- 9.3 Brazil
- 9.4 Argentina
10 Middle East & Africa
- 10.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2028)
- 10.2 Turkey
- 10.3 Saudi Arabia
- 10.4 UAE
11 SERD (Selective Estrogen Receptor Degrader) Drugs Market Dynamics
- 11.1 SERD (Selective Estrogen Receptor Degrader) Drugs Industry Trends
- 11.2 SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
- 11.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Challenges
- 11.4 SERD (Selective Estrogen Receptor Degrader) Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Disclaimer
Summary:
Get latest Market Research Reports on SERD (Selective Estrogen Receptor Degrader) Drugs. Industry analysis & Market Report on SERD (Selective Estrogen Receptor Degrader) Drugs is a syndicated market report, published as Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Report, History and Forecast 2017-2028, Breakdown Data by Companies, Key Regions, Types and Application. It is complete Research Study and Industry Analysis of SERD (Selective Estrogen Receptor Degrader) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
